

EN

E-000623/2021

Answer given by Ms Kyriakides
on behalf of the European Commission
(30.4.2021)

1. Via its EU Strategy for COVID-19 vaccines¹ the Commission has secured access for EU Member States to such vaccines as soon as they become available, and with four vaccines having been authorised for the EU market – from BioNTech/Pfizer, Moderna, AstraZeneca and Johnson & Johnson – vaccination is ongoing in countries, including Spain. While the vaccines secured via the Strategy are obviously primarily intended for Member States, them being the actual purchasers of the vaccines, all countries in the world have been affected by the pandemic and need vaccines. No country is safe until all countries are safe. The advance purchase agreements negotiated with vaccine manufactures allow Member States, such as Spain, to resell vaccines to other countries. This is however a matter for the Member State concerned to decide with the consent of the vaccine manufacturer from which the vaccines were initially purchased.

2. As stated above, all countries in the world have been affected by the pandemic. This also applies to high-income countries, such as Andorra. There could be a particular need for EU Member States, such as Spain, to provide vaccines to countries with which they share a border, such as Andorra.

¹ <https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1597339415327&uri=CELEX%3A52020DC0245>